Lucid Diagnostics Announces Pricing of Initial Public Offering
NEW YORK–(BUSINESS WIRE)–$LUCD–Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the pricing of its […]